HALO vs. MTD: Halozyme Therapeutics vs. Mettler-Toledo Stock Comparison

November 11, 2026

How do Halozyme Therapeutics (HALO) and Mettler-Toledo (MTD) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Halozyme Therapeutics (HALO) and Mettler-Toledo (MTD) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but HALO is classified in Biotechnology while MTD is classified in Life Sciences Tools & Services.

Company profile comparison for Halozyme Therapeutics (HALO) and Mettler-Toledo (MTD)
Profile Item	HALO	MTD
Name	Halozyme Therapeutics Inc.	Mettler-Toledo International Inc.
Country/Region	United States	Switzerland
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Life Sciences Tools & Services
GICS Sub-Industry	Biotechnology	Life Sciences Tools & Services
Market Capitalization	11.81 billion USD	34.25 billion USD
Currency	USD	USD
Exchange	Nasdaq	NYSE
Listing Date	March 16, 2004	November 14, 1997
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

HALO

MTD

GSPC

Halozyme Therapeutics (HALO) vs. Mettler-Toledo (MTD), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Halozyme Therapeutics (HALO) and Mettler-Toledo (MTD). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Halozyme Therapeutics (HALO) and Mettler-Toledo (MTD). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Halozyme Therapeutics (HALO) and Mettler-Toledo (MTD)
Metric	HALO	MTD
Total Return (1Y)	50.94%	21.58%
Total Return (3Y, Annualized)	41.08%	19.54%
Total Return (5Y, Annualized)	21.68%	2.36%

Risk Profile

Drawdown History

HALO

MTD

GSPC

Halozyme Therapeutics (HALO) vs. Mettler-Toledo (MTD), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Halozyme Therapeutics (HALO) and Mettler-Toledo (MTD). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Halozyme Therapeutics (HALO) and Mettler-Toledo (MTD)
Metric	HALO	MTD
Volatility (1Y, Annualized)	41.19%	31.70%
Beta (5Y)	0.96	1.15
Max Drawdown (5Y)	-49.06%	-43.47%
Avg. Volume (3M)	2.29M	197.80K

Risk-Adjusted Performance

Risk-Return Positioning

HALO and MTD are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Halozyme Therapeutics (HALO) and Mettler-Toledo (MTD)
Metric	HALO	MTD
Sharpe Ratio (1Y)	1.13	0.55
Sortino Ratio (1Y)	1.78	0.75

Profitability

ROE (TTM)

Capital efficiency shows on one side only: Halozyme Therapeutics (HALO) earns 216.38% on shareholders’ equity, ranked against its industry; Mettler-Toledo (MTD) has no ROE this period.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

216.38%

HALO: 216.38%
Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%
MTD: --

Halozyme Therapeutics (HALO) vs. Mettler-Toledo (MTD): MTD does not report ROE, so it has no value marker; HALO is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Net Margin (TTM)

Both Halozyme Therapeutics (HALO) at 26.93% and Mettler-Toledo (MTD) at 22.25% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.93%

HALO: 26.93%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

22.25%

MTD: 22.25%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Halozyme Therapeutics (HALO) vs. Mettler-Toledo (MTD): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Halozyme Therapeutics (HALO) at 59.84% and Mettler-Toledo (MTD) at 28.70% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

59.84%

Max: 83.12%
HALO: 59.84%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

28.70%

Max: 83.12%
MTD: 28.70%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Halozyme Therapeutics (HALO) vs. Mettler-Toledo (MTD): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Halozyme Therapeutics (HALO) and Mettler-Toledo (MTD)
Metric	HALO	MTD
ROE (TTM)	216.38%	--
ROA (TTM)	22.42%	20.09%
Net Margin (TTM)	26.93%	22.25%
Operating Margin (TTM)	59.84%	28.70%
Gross Margin (TTM)	77.74%	59.16%

Growth

Revenue Growth

Both Halozyme Therapeutics (HALO) at 37.55% and Mettler-Toledo (MTD) at 3.98% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Halozyme Therapeutics (HALO) vs. Mettler-Toledo (MTD): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Halozyme Therapeutics (HALO) at -25.36% and Mettler-Toledo (MTD) at 3.88% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Halozyme Therapeutics (HALO) vs. Mettler-Toledo (MTD): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Halozyme Therapeutics (HALO) and Mettler-Toledo (MTD)
Metric	HALO	MTD
Revenue Growth (YoY)	37.55%	3.98%
Revenue Growth (3Y CAGR)	28.38%	0.90%
EPS Growth (YoY)	-25.36%	3.88%
EPS Growth (3Y CAGR)	21.14%	3.06%

Financial Strength

Current Ratio (MRQ)

Halozyme Therapeutics (HALO) at 3.88 keeps current ratio within its industry’s typical mid-range, while Mettler-Toledo (MTD) at 1.10 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for MTD.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.88

Max: 25.13
Q3: 12.13
Median: 5.52
HALO: 3.88
Q1: 2.47
Min: 0.10

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.10

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
MTD: 1.10
Min: 0.10

Halozyme Therapeutics (HALO) vs. Mettler-Toledo (MTD): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Only one side’s leverage can be read here: Mettler-Toledo (MTD) carries debt-to-equity ratio of 26.06 against its industry range, while Halozyme Therapeutics (HALO) reports no figure this period.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00
HALO: --

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.06

MTD: 26.06
Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

Halozyme Therapeutics (HALO) vs. Mettler-Toledo (MTD): HALO does not report debt-to-equity ratio, so it has no value marker; MTD is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Financial Strength Metrics

Financial strength metrics for Halozyme Therapeutics (HALO) and Mettler-Toledo (MTD)
Metric	HALO	MTD
Current Ratio (MRQ)	3.88	1.10
Debt / Equity (MRQ)	--	26.06
Net Debt / EBITDA	1.90	1.58

Dividends

Dividend Yield (TTM)

Neither Halozyme Therapeutics (HALO) nor Mettler-Toledo (MTD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

HALO: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MTD: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Halozyme Therapeutics (HALO) vs. Mettler-Toledo (MTD): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Halozyme Therapeutics (HALO) nor Mettler-Toledo (MTD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

HALO: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MTD: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Halozyme Therapeutics (HALO) vs. Mettler-Toledo (MTD): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Halozyme Therapeutics (HALO) and Mettler-Toledo (MTD)
Metric	HALO	MTD
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

Both Halozyme Therapeutics (HALO) at 25.91 and Mettler-Toledo (MTD) at 37.38 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.91

Max: 85.34
Q3: 43.46
Median: 26.69
HALO: 25.91
Q1: 13.30
Min: 0.07

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

37.38

Max: 85.34
Q3: 43.46
MTD: 37.38
Median: 26.69
Q1: 13.30
Min: 0.07

Halozyme Therapeutics (HALO) vs. Mettler-Toledo (MTD): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Halozyme Therapeutics (HALO) at 6.55 and Mettler-Toledo (MTD) at 8.16 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.55

Max: 58.18
Q3: 25.77
Median: 7.30
HALO: 6.55
Q1: 3.01
Min: 0.01

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.16

Max: 58.18
Q3: 25.77
MTD: 8.16
Median: 7.30
Q1: 3.01
Min: 0.01

Halozyme Therapeutics (HALO) vs. Mettler-Toledo (MTD): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Halozyme Therapeutics (HALO) reports a negative P/B ratio of -213.67, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Mettler-Toledo (MTD) reports 442.71, ranking against industry peers normally.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

-213.67

Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59
HALO: -213.67

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

442.71

MTD: 442.71
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

Halozyme Therapeutics (HALO) vs. Mettler-Toledo (MTD): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Halozyme Therapeutics (HALO) and Mettler-Toledo (MTD)
Metric	HALO	MTD
P/E Ratio (TTM)	25.91	37.38
P/S Ratio (TTM)	6.55	8.16
P/B Ratio (MRQ)	-213.67	442.71
Free Cash Flow Yield (TTM)	3.48%	1.97%